Review Articles

OPEN ACCESS

Pharmaco-Epigenomic Reprogramming as the Next Therapeutic Frontier

Shiv Kumar Bhardwaj *

Columbia Institute of Pharmacy, Tekari, Near Vidhansabha Road, Raipur-493111, Chhattisgarh, India

ARTICLE INFO

Article history:
Received 24 February 2026
Accepted 14 March 2026

Keywords:
Pharmaco-epigenomics;
Epigenetic reprogramming;
Precision medicine;
DNA methylation;
Histone modifications

ABSTRACT

Background Epigenetic dysregulation is a central hallmark of numerous complex diseases, including cancer, neurodegenerative disorders, metabolic syndromes, and immune-mediated conditions. Unlike genetic mutations, epigenetic alterations are reversible, rendering them highly attractive therapeutic targets. Recent advances in pharmaco-epigenomics-integrating pharmacology with epigenomic profiling-have opened unprecedented opportunities for precision medicine. **Objective** This review critically synthesizes current knowledge on pharmaco-epigenomic reprogramming, highlighting mechanistic insights, therapeutic agents, technological advances, clinical progress and emerging challenges. **Methods** A structured literature search was conducted across PubMed, Scopus, and Web of Science databases (2020-2025), focusing on epigenetic drugs, pharmaco-epigenomic biomarkers and translational applications. Studies were screened following PRISMA-inspired trend-based review methodology. **Results** Epigenetic therapeutics, including DNA methyltransferase inhibitors, histone modification modulators, and chromatin remodelling agents, demonstrate disease-modifying potential across oncology and non-oncological domains. Integration of multi-omics, AI-driven drug response modeling, and single-cell epigenomics is reshaping therapeutic stratification. However, challenges such as off-target effects, epigenetic plasticity and interindividual variability remain unresolved. **Conclusion** Pharmaco-epigenomic reprogramming represents a transformative therapeutic paradigm. Future success depends on precise targeting, combinatorial strategies and robust epigenomic biomarkers to enable personalized and durable clinical outcomes.

1. Introduction

1.1. Global disease burden and epigenetic dysregulation

Chronic and complex diseases account for over 70% of global mortality with cancer, cardiovascular diseases, neurodegenerative disorders and metabolic syndromes representing the largest contributors. While genetic predisposition plays a role, accumulating evidence indicates that epigenetic dysregulation acts as a critical interface between environmental exposures and disease phenotypes [1]. Epigenetic mechanisms-including DNA methylation, histone modifications and non-coding RNAs-govern gene expression without altering DNA sequence [2]. Aberrant epigenetic landscapes have been consistently observed in malignancies, aging-related disorders, autoimmune diseases and psychiatric conditions [3].

1.2. Rationale for pharmaco-epigenomic reprogramming

Conventional pharmacotherapy often fails to address disease heterogeneity and adaptive resistance. In contrast, pharmaco-epigenomic reprogramming aims to therapeutically reset pathological epigenetic states, thereby restoring normal transcriptional programs. The reversibility of epigenetic modifications positions them as ideal targets for next-generation therapeutics [4].

2. Methodology

2.1. Literature search strategy

A comprehensive literature search was performed across PubMed, Scopus, and Web of Science for studies published between January 2020 and January 2025 [5].

* *Corresponding author: Shiv Kumar Bhardwaj.*
ISSN: 3068-9376/ This work is licensed under a Creative Commons Attribution 4.0 International License.
DOI: 10.64904/fpm2026.023

Search terms included: The literature search employed a combination of controlled vocabulary and free-text keywords, including but not limited to pharmaco-epigenomics, epigenetic reprogramming, epigenetic therapeutics, DNA methyltransferase inhibition, histone deacetylase inhibition, chromatin remodelling-based interventions, and precision epigenetic medicine [6].

2.2. Inclusion and exclusion Criteria

Studies were included if they were peer-reviewed original research or review articles published in English, involving human, translational, or advanced preclinical research and focused on therapeutic epigenetic modulation. Excluded were non-therapeutic epigenetic studies, editorials, commentaries, conference abstracts and publications prior to 2020 unless considered seminal.

2.3. Data extraction and synthesis

Data were systematically extracted and thematically analyzed to identify trends in mechanisms of action, therapeutic classes, clinical development stages and technological integration.

3. Mechanistic foundations of epigenomic reprogramming

3.1. DNA methylation modulation

DNA methyltransferases (DNMTs) catalyze the methylation of cytosine residues, often resulting in transcriptional repression. In cancer, aberrant hypermethylation of tumor suppressor genes is a hallmark event. Therapeutically, agents such as Azacitidine, Decitabine, and Guadecitabine induce passive DNA demethylation to reactivate gene expression, although their clinical utility is constrained by cytotoxicity and limited target specificity [7].

3.2. Histone modification targeting

Histone acetylation and methylation dynamically regulate chromatin accessibility. Histone-targeting drugs, such as HDAC inhibitors (e.g., Vorinostat, Panobinostat) and HMT inhibitors like Tazemetostat (an EZH2 inhibitor), have therapeutic potential beyond oncology, including applications in neurodegenerative and inflammatory disorders [8].

3.3. Chromatin remodelling and reader proteins

BET bromodomain inhibitors (e.g., JQ1) disrupt transcriptional elongation of oncogenes such as MYC, highlighting the importance of epigenetic "reader" proteins in disease maintenance [9].

4. Pharmaco-epigenomics in precision medicine

4.1. Biomarker-driven epigenetic therapies

Epigenomic biomarkers-including CpG methylation signatures and histone modification patterns-enable patient stratification and therapeutic response prediction [10].

4.2. Multi-omics integration

The convergence of epigenomics with transcriptomics, proteomics and metabolomics enhances mechanistic resolution and drug response modeling [11].

5. Emerging technologies shaping the field

5.1. Single-cell epigenomics

Single-cell ATAC-seq and methylome profiling reveal intra-tumoral epigenetic heterogeneity, guiding adaptive therapeutic strategies [12].

5.2. AI and machine learning applications

Artificial intelligence algorithms are increasingly employed to predict epigenetic drug sensitivity, identify novel epigenetic targets, and optimize combinatorial treatment regimens [13].

Table 1 - Major classes of epigenetic therapeutics [14]

Class	Target	Representative Drugs	Clinical Status
DNMT inhibitors	DNA methylation	Azacitidine	Approved
HDAC inhibitors	Histone acetylation	Vorinostat	Approved
BET inhibitors	Bromodomain readers	JQ1	Preclinical
EZH2 inhibitors	Histone methylation	Tazemetostat	Approved

Table 2 - Advantages and Limitations of Epigenetic Therapies [15]

Advantages	Limitations
Reversible targets	Off-target effects
Broad disease applicability	Epigenetic plasticity
Synergistic potential	Limited specificity



Fig.1 - Conceptual Framework of Pharmaco-Epigenomic Reprogramming

5.3. Mechanisms and translational frameworks for drug-epigenomic reprogramming

The mechanism and transformation pathway of drug epigenomic reprogramming are mainly induced by a variety of epigenetic drugs, including DNMT inhibitors, HDAC inhibitors, BET inhibitors, and EZH2 inhibitors, through DNA demethylation, histone acetylation, and chromatin remodeling. These modifications lead to open chromatin structure and gene expression reset, promoting therapeutic effects such as tumor suppression, neuroprotection, anti-inflammatory, and metabolic regulation. Integrating precision medicine through biomarker selection enables personalized treatment and long-lasting clinical response.

Fig.1 illustrates the mechanistic and translational framework of pharmaco-epigenomic reprogramming. On the left, various classes of epigenetic drugs-including DNMT inhibitors, HDAC inhibitors, BET inhibitors and EZH2 inhibitors-target specific epigenetic mechanisms to modulate gene expression. The central panel depicts epigenetic modulation, showing DNA demethylation, histone acetylation and chromatin remodeling which collectively reset gene expression and convert chromatin into an open, transcriptionally active state. These molecular changes drive therapeutic outcomes such as tumor suppression, neuroprotection, anti-inflammatory effects and metabolic regulation. The lower section highlights the integration of precision medicine where biomarker selection guides personalized therapy, ultimately achieving a durable therapeutic response. Overall, the figure emphasizes the link between epigenetic interventions, gene expression remodeling and clinical translation in a patient-tailored context.

6. Future Perspectives and Research Gaps

Future research should focus on developing locus-specific epigenetic editors, evaluating long-term safety, integrating real-world epigenomic data and addressing ethical considerations in epigenetic manipulation with emerging CRISPR-based epigenome editing tools offering potential solutions to current specificity limitations.

7. Conclusion

Pharmaco-epigenomic reprogramming heralds a paradigm shifts from symptomatic treatment to mechanistic disease modification. With continued technological innovation and biomarker-driven precision strategies, epigenetic therapeutics are poised to redefine future clinical practice.

A.1. Abbreviations

AI: Artificial Intelligence
ATAC-seq: Assay for Transposase-Accessible Chromatin
BET: Bromodomain and Extra-Terminal
DNMT: DNA Methyltransferase
HDAC: Histone Deacetylase

A.2. Acknowledgements

The authors express their gratitude to the Principal of Columbia Institute of Pharmacy, Raipur, Chhattisgarh, India, for providing the necessary infrastructural and library facilities to complete this review.

REFERENCE:

[1] Hacker K. The Burden of Chronic Disease. Mayo Clin Proc Innov Qual Outcomes 2024; 8:112–9. https://doi.org/10.1016/j.mayocpiqo.2023.08.005.
[2] Epigenetic and experimental approaches influencing non-coding RNAs, 2025, p. 65–79. https://doi.org/10.1016/bs.pmbts.2025.05.001.
[3] Gaetano C, Atlante S, Gottardi Zamperla M, Barbi V, Gentilini D, Illi B, et al. The COVID-19 legacy: consequences for the human DNA methylome and therapeutic perspectives. Geroscience 2024;47:483–501. https://doi.org/10.1007/s11357-024-01406-7.
[4] Salvati A, Melone V, Giordano A, Lamberti J, Palumbo D, Palo L, et al. Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies. J Transl Med 2025;23:837. https://doi.org/10.1186/s12967-025-06856-x.
[5] Tong L-K, Tam H-L, Mao A-M. A Bibliometric Review of Person-Centered Care Research 2010–2024. Healthcare 2025;13:1267. https://doi.org/10.3390/healthcare13111267.
[6] Cao X, Cui X, Badehnoosh B. Epigenetic Modulation and Brain Function in Parkinson's Disease: The Role of Exercise Alone or Combined With Polyphenols. Food Sci Nutr 2025;13. https://doi.org/10.1002/fsn3.70696.
[7] Kim DJ. The Role of the DNA Methyltransferase Family and the Therapeutic Potential of DNMT Inhibitors in Tumor Treatment. Current Oncology 2025;32:88. https://doi.org/10.3390/curroncol32020088.
[8] Zhang Y. Reduced EZH1/2 expression in imipridone-treated cells correlates with synergy following combinations with EZH1/2 or HDAC inhibitors in diffuse glioma and other tumors. Am J Cancer Res 2025;15:1307–20. https://doi.org/10.62347/DZAT5333.
[9] Yasser R, Arafa KK, Sedky NK, Sidaros KR, Arafa RK. BET Bromodomain Inhibitors as an Emerging Class of Anticancer Agents, 2025, p. 883–911. https://doi.org/10.1007/978-3-032-00771-1_401.
[10] Imran K, Iqbal MJ, Ahmed MM, Khalid A, Cortés H, Reyes-Hernández OD, et al. Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies. Medical Oncology 2025;42:359. https://doi.org/10.1007/s12032-025-02905-z.
[11] Mukherjee A, Abraham S, Singh A, Balaji S, Mukunthan KS. From Data to Cure: A Comprehensive Exploration of Multi-omics Data Analysis for Targeted Therapies. Mol Biotechnol 2025;67:1269–89. https://doi.org/10.1007/s12033-024-01133-6.
[12] Dong M, Wang L, Hu N, Rao Y, Wang Z, Zhang Y. Integration of multi-omics approaches in exploring intra-tumoral heterogeneity. Cancer Cell Int 2025;25:317. https://doi.org/10.1186/s12935-025-03944-2.
[13] Sahoo K, Lingasamy P, Khatun M, Sudhakaran SL, Salumets A, Sundararajan V, et al. Artificial Intelligence in cancer epigenomics: a review on advances in pan-cancer detection and precision medicine. Epigenetics Chromatin 2025;18:35. https://doi.org/10.1186/s13072-025-00595-5.
[14] Ma C, Cheng J, Gu J, Wang Q. Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications. Molecular Biomedicine 2025;6:132. https://doi.org/10.1186/s43556-025-00373-5.
[15] Gao T, Fu S, Quan X, Sun J, Jiang M, Li J. Advancing Epigenetic Combination Therapy in Oncology: Multifunctional Nano-Drug Delivery Systems for Synergistic Efficacy and Precision Modulation. Int J Nanomedicine 2025;Volume 20:14853–83. https://doi.org/10.2147/IJN.S566173.